Findings

What do systematic reviews say?

4,929 questions · 15,213 findings · 2,394 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,213 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

High‐dose colchicine vs placebo

Function of target joint ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Pain ‐ not reported · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Reduction of inflammation ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Function of target joint ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs NSAIDs

Reduction of inflammation ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs NSAIDs

Function of target joint ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs NSAIDs

Serious adverse events · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs NSAIDs

Withdrawals due to adverse events · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs placebo

Reduction of inflammation ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs placebo

Function of target joint ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose colchicine vs placebo

Pain ‐ not reported · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Complex information, support and training interventions vs information only

Use of health and social resources ‐ not reported · Informal caregivers of people with dementia

The review found no eligible studies for this question.

1 finding from 1 review

Remotely delivered information, training and support for informal caregivers of people with dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warm saline vs room temperature saline

Quality of hysteroscopic view · women undergoing outpatient hysteroscopy

The review found no eligible studies for this question.

1 finding from 1 review

Uterine distension media for outpatient hysteroscopy 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Outcomes · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fondaparinux vs heparin

Quality of life ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fondaparinux vs heparin

Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fondaparinux vs heparin

Thrombocytopenia · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found